FierceMedTech opens nominations for the 2019 Fierce 15

FierceMedTech Fierce 15

Our 2018 picks for the FierceMedTech Fierce 15 showcased the innovative companies we believe can make strong, tangible impacts—not just by moving their individual needles past the limits of today’s medical technology, but by chasing breakthroughs that could move the field forward as a whole.

They included tech-powered upgrades of decades-old devices and techniques, where injuries, failures and mortality rates had stagnated. Some companies developed new methods to query the body itself, diving into its cells and proteins to provide more precise pictures of disease. Others zoomed outwards, using digital biomarkers and therapeutics to capture vast streams of data and sift them for ways toward better health, both mental and physical.

Now, we’re asking for your help in finding the next class of Fierce 15, so we can keep spotlighting the work of the most promising startups in the industry. Nominations are open for private companies from all over the world, and those at different levels of development.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Please enter their names and the reasons you think they’re fierce in the form below—by Monday, Dec. 16. The full list of last year’s Fierce 15 is available here.

 

Read more on

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.